CJC-1295

Classification

Growth-hormone–releasing hormone analogue (research only)

Approval status

Research only · Not approved for human use

Research status

Investigational GHRH analogue family. Not an approved medicine. Name collision: DAC vs non-DAC research products are not interchangeable.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

Tetrasubstituted GRF(1–29) analogue; ‘CJC-1295’ often includes a Drug Affinity Complex (DAC) maleimidopropionyl lysine for albumin conjugation. ‘Mod GRF 1-29’ without DAC is a different pharmacokinetic entity frequently confused in grey-market naming.

Primary biological target

GHRH receptor (DAC-modified GHRH analogue in the original CJC-1295 construct)

Half-life

Original Drug-Affinity-Complex (DAC) construct was designed for multi-day GH-axis stimulation; ‘no DAC’ research fragments are pharmacokinetically different

Routes investigated

Subcutaneous

Human evidence level

C — Limited or early human evidence

An unapproved GHRH analogue. Not a consumer GH secretagogue product. Not sold here.

Synthetic GHRH analogue; the published CJC-1295 construct used albumin-binding (DAC) chemistry.

Proposed mechanism

Proposed mechanism: GHRH-receptor agonism increases pituitary GH. The albumin-binding DAC form prolongs exposure in published clinical pharmacology. Mechanism not yet fully established as therapy. Unregulated ‘CJC-1295 without DAC’ products should not be assumed to match Teichman et al. PK.

Would be expected to raise GH/IGF-1 if bioactive and bioavailable — which is precisely why unregulated use is inappropriate without specialist endocrinology and is not approved.

• Growth-hormone axis

  C · Limited or early human evidence

  Early human research has examined GH and IGF-1 after CJC-1295 in clinical pharmacology.^[1]

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: C · Limited or early human evidence

Animal, cell and in-vitro findings are listed separately from human effects.

GHRH analogue pharmacology is known as a class.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

1. Teichman et al. 2006

   Dose: Dose-ranging (see paper) µg/kg

   Route: Subcutaneous

   Frequency: Intermittent in the pharmacology protocol

   Duration: Study-specific

   Population: Healthy adults

   Purpose: GH/IGF-1 pharmacodynamics of DAC CJC-1295

   ^[1]

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Half-life

Multi-day IGF-1 effect described for DAC CJC-1295; not for unnamed research powders

Insufficient reliable evidence identified that grey-market ‘no DAC’ vials match published DAC PK.

Injection-site reactions and GH-axis effects possible; labelled AE table absent.

Unknowns. Long-term safety unknown. Development of related GHRH analogues had cardiovascular safety questions in other programmes — do not assume safety.

Contraindications. Not for human use. Malignancy history would be a major clinical concern for GH-axis drugs.

Australia — TGA

Not approved.

United States — FDA

Not approved.

European Union — EMA

Not approved.

1. [1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295

   Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 J Clin Endocrinol Metab. 2006. doi:10.1210/jc.2005-1538 PMID 16352683

   PMID 16352683DOI